Details of the Drug

General Information of Drug (ID: DMYEZ5J)

Drug Name
Romilkimab
Synonyms SAR156597
Indication
Disease Entry ICD 11 Status REF
Idiopathic pulmonary fibrosis CB03.4 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
UNII
O8HNJ174XS
DrugBank ID
DB16318
TTD ID
DF5R7E

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-13 (IL13) TT0GVCH IL13_HUMAN Inhibitor [2]
Interleukin-4 (IL4) TTLGTKB IL4_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02345070) Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (ESTAIR). U.S. National Institutes of Health.
2 A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.